114 related articles for article (PubMed ID: 11435075)
1. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours.
Sato Y; Kashimoto S; MacDonald JR; Nakano K
Eur J Cancer; 2001 Jul; 37(11):1419-28. PubMed ID: 11435075
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
Hammond LA; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Eur J Cancer; 2000 Dec; 36(18):2430-6. PubMed ID: 11094320
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.
Kelner MJ; McMorris TC; Estes L; Samson KM; Bagnell RD; Taetle R
Eur J Cancer; 1998 May; 34(6):908-13. PubMed ID: 9797706
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.
Sherman CA; Herndon JE; Watson DM; Green MR;
Lung Cancer; 2004 Sep; 45(3):387-92. PubMed ID: 15301880
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
8. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
9. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
10. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
[TBL] [Abstract][Full Text] [Related]
11. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.
Kelner MJ; McMorris TC; Estes LA; Oval MY; Rojas RJ; Lynn JR; Lanham KA; Samson KM
Anticancer Drugs; 2000 Mar; 11(3):217-24. PubMed ID: 10831281
[TBL] [Abstract][Full Text] [Related]
14. The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.
Breistøl K; Hendriks HR; Berger DP; Langdon SP; Fiebig HH; Fodstad O
Eur J Cancer; 1998 Sep; 34(10):1602-6. PubMed ID: 9893636
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
16. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
17. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
[TBL] [Abstract][Full Text] [Related]
18. A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.
Orienti I; Salvati V; Sette G; Zucchetti M; Bongiorno-Borbone L; Peschiaroli A; Zolla L; Francescangeli F; Ferrari M; Matteo C; Bello E; Di Virgilio A; Falchi M; De Angelis ML; Baiocchi M; Melino G; De Maria R; Zeuner A; Eramo A
J Exp Clin Cancer Res; 2019 Aug; 38(1):373. PubMed ID: 31439019
[TBL] [Abstract][Full Text] [Related]
19. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
